Private equity buyers eye offer for GlaxoSmithKline's drinks brands

Private equity firms Blackstone and Lion Capital are together eyeing an offer for GlaxoSmithKline's ($GSK) drinks brands Lucozade and Ribena. Up for sale as the U.K.-based drugmaker sheds lower-performing and non-core assets, the brands could fetch a bid worth more than £1 billion. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.